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Background: To date, the different treatment modalities for high-risk prostate cancer (Pca) have not been compared
in any sufficiently large-scale, prospective, randomized clinical trial. We used propensity-score matching analysis to
compare the oncological outcomes of high-risk prostate cancer between patients treated with radical prostatectomy
(RP) and those treated with radiation therapy (RT).
Methods: We studied 216 patients who received neoadjuvant therapy followed by RP (RP cohort) and 81 patients
who received neoadjuvant androgen-deprivation therapy (ADT) followed by RT (RT cohort). The RP cohort received a
luteinizing hormone-releasing hormone agonist and estramustine phosphate (280 mg/day) for 6 months prior to RP.
The RT cohort received ADT for at least 6 months prior to RT using a 3-dimensional conformal radiotherapy technique.
The total radiation dose was 70 to 76 Gy administered at 2 Gy/fraction.
Results: Propensity-score matching identified 78 matched pairs of patients. The 3-year overall survival rates were 98.3%
and 92.1% in the RP and RT groups, respectively (P = 0.156). The 3-year biochemical recurrence-free survival rates were
86.4% and 89.4% in the RP and RT groups, respectively (P = 0.878).
Conclusions: Our study findings may suggest almost identical cancer control of RP and RT with appropriate
neoadjuvant therapy in high-risk Pca. Therefore, issues of health-related quality of life may have an important impact on
decision making in treatment of high-risk Pca.
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Individuals with prostate-specific antigen (PSA) levels
of ≥20 ng/mL, Gleason scores of ≥8, or clinical stage
T2c/T3 tumors are defined as high-risk prostate cancer
(Pca) patients [1]. Treatment options for high-risk Pca
include external beam-radiation therapy (EBRT) with* Correspondence: coyama@cc.hirosaki-u.ac.jp
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with a combination of brachytherapy, EBRT, and ADT;
and radical prostatectomy (RP) with neoadjuvant or adju-
vant therapy. To date, no sufficiently large-scale, pro-
spective, randomized clinical trials have compared the
abovementioned treatment options. Thus, optimal man-
agement strategies for high-risk Pca patients have not
been established. Previous studies comparing RP and
EBRT were difficult to interpret because of biased treat-
ment selection criteria, incomplete follow-up data, varied. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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[2]. Above all, several studies comparing Pca treatment
options have either overlooked medical comorbidities,
because of lack of relevant information [3], or have
attempted to control for measured comorbidities using
statistical methods [4,5].
Therefore, we aimed to evaluate the overall survival (OS)
and the biochemical recurrence-free survival (BRFS) rates
of high-risk Pca patients who underwent either RP or
EBRT using propensity-score matching analyses to adjust
for treatment selection bias.
Methods
Patient selection
We conducted a retrospective chart review of 329 con-
secutive high-risk Pca patients treated at our institution
between July 2004 and July 2012. Thirty-two patients
who underwent only RP were excluded. We selected 216
patients who received neoadjuvant therapy followed by
RP (the RP cohort) and 81 patients who received neoad-
juvant ADT followed by EBRT (the RT cohort). The
study protocol and informed consent documents was
reviewed and approved by the Hirosaki University insti-
tutional review board.
Treatment
A single pathologist reviewed the diagnostic biopsy spec-
imens and surgical specimens. We have previously re-
ported the active effect of luteinizing hormone-releasing
hormone (LHRH) plus low-dose estramustine phosphate
(EMP; LHRH + EMP) for high-risk Pca patients [6].
Patients in the RP cohort received LHRH (leuprolide
(11.25 mg) or goserelin acetate (10.8 mg) every 3 months)
and EMP (280 mg/day) for 6 months prior to RP [6]. Ret-
ropubic RP was performed as previously described in detail
[7]. All patients in the RP cohort underwent the same
lymphadenectomy procedure, which included removal of
the bilateral obturator lymph nodes.
RT patients received ADT (LHRH and an antiandrogen)
for at least 6 months prior to receiving EBRT. All patients
were treated using a 3-dimensional conformal radio-
therapy (3D-CRT) technique. The clinical target volume
included the entire prostate and the bases of the sem-
inal vesicles. A safety margin of 10 mm was added in
all directions except posteriorly, where a 6-mm margin
was added, to create the planning target volume. The
total radiation dose was 70 to 76 Gy delivered in 2 Gy/
fraction at 5 fractions/week.
Follow-up evaluations
All patients were followed up by assessing serum PSA
and testosterone levels every 3 months for 5 years and
every 6 months thereafter. Pretreatment serum PSA
levels were measured within 1 month of RP or EBRTadministration. No patient was lost to follow-up in this
study.
For RP-treated patients, disease recurrence or PSA fail-
ure was defined as serum PSA levels exceeding 0.2 ng/mL.
If PSA levels did not decrease to less than 0.2 ng/mL after
surgery, the date of RP was defined as the date of disease
recurrence. For EBRT-treated patients, PSA failure was de-
fined according to the 2006 consensus statement by the
American Society of Therapeutic Radiation and Oncology
[8]. PSA levels rising by 2 ng/mL or more above the nadir
PSA levels is currently defined as biochemical failure after
EBRT [8].
Statistical analysis
To reduce the effect of treatment selection bias and po-
tential confounding factors, we performed propensity-
score matching analysis [9]. Propensity scores were
calculated for each patient using multivariate logistic re-
gression analysis including the following covariates: age,
pretreatment PSA levels, biopsy Gleason scores, and clin-
ical tumor staging. Tumors were staged according to the
2002 Staging Manual by the American Joint Committee
on Cancer Staging [10]. The Gleason scores for prostate
biopsy cores and surgical specimens were determined
according to the 2005 guidelines by the International
Society of Urological Pathology [11]. The predicted values
according to the regression model estimated the propen-
sity of each patient for receiving RP or EBRT according
to his/her baseline characteristics. The differences be-
tween the two groups were assessed by fitting a logistic
regression model using treatment as the response variable
and baseline characteristics as covariables. Data were ana-
lyzed using IBM SPSS Statistics 20 software (International
Business Machines Corp., New York, USA). OS and BRFS
rates were analyzed using the Kaplan- Meier estimator.
The relationship between survival and subgroup clas-
sification was analyzed using the log- rank test. All P values




Propensity-score matching identified 78 matched pairs
of patients. Table 1 shows the pretreatment clinical char-
acteristics of the two groups. No differences were noted
in age, initial PSA levels, biopsy Gleason scores, or clinical
T staging between the two groups. The median follow-up
periods of the RP- and EBRT-treated patients were not sig-
nificantly different.
In the RT cohort, the median duration of ADT prior
to receiving RT was 12 months (interquartile range: 9 to
16 months). Fifty-four patients (69%) received RT at a dose
of 70 Gy, and 24 patients (31%) received RT at a dose of
74 Gy.
Table 1 Pretreatment clinical characteristics categorized
according to treatment administered to 156 patients with


























aP values indicate statistical significance.
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All patients in the RP cohort were evaluated for patho-
logical response. Regarding the pathological T stage, 5%,
59%, and 36% of patients had pT0, pT2, and pT3 tumors,
respectively. Seven patients (9%) had positive surgical mar-
gins in the surgical specimens. None of the patients had re-
ceived adjuvant therapy, including ADT or RT.
Oncological outcomes
The 3-year OS rates were 98.3% and 92.1% for the RP
and RT cohorts, respectively (P = 0.156; Figure 1). At the
time of analysis, 5 RT patients had died. The causes of
death were prostate cancer, colorectal cancer, hepatocel-
lular carcinoma, cerebral hemorrhage, and chronic heart
failure. One patient from the RP cohort committed sui-
cide. The 3-year BRFS rates were 86.4% and 89.4% in the
RP and RT cohorts, respectively (P = 0.878; Figure 2). At
the time of analysis, PSA failure had occurred in 11 RT
and 9 RP patients. These patients did not show clinical
recurrence except for 1 RT-treated patient. In the RP co-
hort, the 3-year BRFS rate was 89.9% (95% confidence
interval (CI): 66.5 to 77.7) in patients who achieved patho-
logical T0/T2 status, and 78.1% (95% CI: 45.4 to 73.9) in
those with T3 status (P = 0.018).
Discussion
To our knowledge, the efficacies of EBRT and RP in
terms of biochemical outcomes, particularly in high-risk
Pca patients, have not been compared in randomized con-
trolled trials; therefore, reliance on observational data has
become mandatory. A comparative analysis of studies in-
volving prostate cancer treated with various modalities wasconducted by the Prostate Cancer Results Study Group.
The analysis, authored by Grimm et al., provides some
insight into the relative effectiveness of surgery and RT for
high-risk disease [12]. Combination therapies involving RT
and brachytherapy plus or minus ADT appear superior to
more localized treatments such as RP alone or RT alone
[12]. In the present study, OS and PSA outcomes following
RP or 3D-CRT were compared among high-risk Pca pa-
tients who were matched for pretreatment predictors.
We administered neoadjuvant LHRH + EMP followed
by RP to high-risk Pca patients. Among high-risk Pca
patients, reported rates of PSA-free survival after RP
alone was 35 to 62% [13,14]. Furthermore, neoadjuvant
hormone therapy before RP reduces the rate of posi-
tive surgical margins, potentially resulting in pathologic
complete responses. However, neoadjuvant ADT has not
been shown to be beneficial for patient outcomes, espe-
cially in terms of PSA-free survival, in randomized trials
[15]. Long-term administration of low-dose EMP may
have a positive impact on the PSA-free survival rate; the
PSA-free survival rate was 86.4% in our study, which was
higher than the values reported by several other clinical
trial [13-15].
In EBRT-treated high-risk Pca patients, an RT dose of
70 Gy may be inadequate to eradicate the disease com-
pletely. Support for this hypothesis came from a ran-
domized dose escalation trial (78 Gy versus 70 Gy) [16],
in which a beneficial effect was noted for all patients in
terms of the 5-year BRFS rate (78% versus 68%; P = 0.03),
and particularly, in patients with a pretreatment PSA level
of >10 to 20 ng/mL (72% versus 43%; P = 0.01). Patients
with locally advanced Pca were found to experience favor-
able survival outcomes in a prospective randomized clinical
trial when ADT was added to EBRT [17].
In fact, a more favorable outcome may be achieved
with neoadjuvant LHRH + EMP and RP or 3D-CRT and
ADT than RP or 3D-CRT alone in high-risk Pca patients.
Our study findings may suggest almost identical cancer
control by RP and RT with appropriate neoadjuvant
therapy in high-risk Pca. On the other hand, it is inter-
esting to note that benefits in terms of BRFS were not
observed after treatment completion in the two groups
in the present study. This observation may be attribut-
able to the differing definition of PSA failure between
RP- and EBRT-treated patients. PSA must reach the
nadir value in patients treated with EBRT, and this can
take 1 to 2 years or occasionally longer [18]. Conversely,
almost all RP-treated patients will achieve the nadir PSA
value within 1 to 2 months or sooner after therapy. There-
fore, clinically meaningful and reliable results require lon-
ger follow-up periods.
Finally, the current study was not performed as a non-
inferiority study to compare the efficacy of RP with the RT
in patients with high-risk Pca. Our findings were limited by
Figure 1 Kaplan- Meier estimate of overall survival (OS). The 3-year OS rate was 98.3% in the high-risk prostate cancer patients treated with
neoadjuvant luteinizing hormone-releasing hormone agonist and estramustine phosphate followed by radical prostatectomy. The 3-year OS rate
was 92.1% in patients treated with neoadjuvant androgen-deprivation therapy followed by radiation therapy (P = 0.156).
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small study sample size. The RP patients received neoadju-
vant LHRH+ EMP, and RT patients received neoadjuvant
LHRH and antiandrogen. Propensity-score analysis is a
method used to reduce bias in observational studies and
matching was limited to available variables. Additionally,Figure 2 Kaplan- Meier estimate of biochemical recurrence-free survi
cancer patients treated with neoadjuvant luteinizing hormone-releasing
prostatectomy and 89.4% in those treated with neoadjuvant androgen-dother factors such as quality of life, continence, and erectile
function, which also affect treatment decisions, were not
evaluated in our study. Therefore, issues of health-related
quality of life may have an important impact on deci-
sion making of treatment in high-risk prostate cancer.
However, our study results may assist in decision-makingval (BRFS). The 3-year BRFS rates were 86.4% in the high-risk prostate
hormone agonist and estramustine phosphate followed by radical
eprivation therapy followed by radiation therapy (P = 0.878).
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randomized clinical trial data are lacking. Future clinical
trials are warranted.
Conclusions
Our study findings may suggest almost identical cancer
control of RP and RT with appropriate neoadjuvant ther-
apy in high-risk Pca. Therefore, issues of health-related
quality of life may have an important impact on decision
making in treatment of high-risk Pca.
Abbreviations
ADT: androgen-deprivation therapy; BRFS: biochemical recurrence-free survival;
EBRT: external beam-radiation therapy; LHRH + EMP: luteinizing hormone-
releasing hormone agonist and estramustine phosphate; OS: overall survival;
Pca: prostate cancer; PSA: prostate-specific antigen; RP: radical prostatectomy;
RT: radiation therapy; 3D-CRT: 3-dimensional conformal radiotherapy.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
TK wrote the manuscript. HY, AI, SH, TY and MA performed clinical follow-up
examinations and contributed to the manuscript. YH reviewed the
pathological specimens. YT, TY and YT contributed to manuscript drafting.
CO was responsible for the concept, design, data interpretation, and critical
revision of the manuscript. All authors read and approved the final version of
the manuscript.
Acknowledgements
No funding was received for the present study.
Author details
1Department of Urology, Hirosaki University Graduate School of Medicine, 5
Zaifucho, Hirosaki 036-8562, Japan. 2Department of Radiology, Hirosaki
University Graduate School of Medicine, 5 Zaifucho, Hirosaki 036-8562, Japan.
Received: 20 September 2013 Accepted: 15 April 2014
Published: 30 April 2014
References
1. Lester-Coll NH, Goldhaber SZ, Sher DJ, D’Amico AV: Death from high-risk
prostate cancer versus cardiovascular mortality with hormone therapy.
Cancer 2013, 119:1808–1815.
2. Hoffman RM, Koyama T, Kang-Hsien F, Albertsen PC, Barry MJ, Goodman M,
Hamilton AS, Potosky AL, Stanford JL, Stroup AM, Penson DF: Mortality after
radical prostatectomy or external beam radiotherapy for localized prostate
cancer. J Natl Cancer Inst 2013, 105:711–718.
3. Abdollah F, Sun M, Thuret R, Jeldres C, Tian Z, Briganti A, Shariat SF, Perrotte P,
Rigatti P, Montorsi F, Karakiewicz PI: A competing-risks analysis of survival after
alternative treatment modalities for prostate cancer patients: 1988-2006. Eur
Urol 2011, 59:88–95.
4. Abdollah F, Schmitges J, Sun M, Jeldres C, Tian Z, Briganti A, Shariat SF,
Perrotte P, Montorsi F, Karakiewicz PI: Comparison of mortality outcomes
after radical prostatectomy versus radiotherapy in patients with
localized prostate cancer: a population-based analysis. Int J Urol 2012,
19:836–844.
5. Kibel AS, Ciezki JP, Klein EA, Reddy CA, Lubahn JD, Haslag-Minoff J, Deasy JO,
Michalski JM, Kallogjeri D, Piccirillo JF, Rabah DM, Yu C, Kattan MW,
Stephenson AJ: Survival among men with clinically localized prostate
cancer treated with radical prostatectomy or radiation therapy in the
prostate specific antigen era. J Urol 2012, 187:1259–1265.
6. Koie T, Ohyama C, Yamamoto H, Hatakeyama S, Yoneyama T, Hashimoto Y,
Kamimura N: Safety and effectiveness of neoadjuvant luteinizing
hormone-releasing hormone agonist plus low-dose estramustine phosphate
in high-risk prostate cancer: a prospective single-arm study. Prostate Cancer
Prostatic Dis 2012, 15:397–401.7. Koie T, Yamamoto H, Hatakeyama S, Kudoh S, Yoneyama T, Hashimoto Y,
Kamimura N, Ohyama C: Minimum incision endoscopic radical
prostatectomy: clinical and oncological outcomes at a single institute.
Eur J Surg Oncol 2011, 37:805–810.
8. Roach M III, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH,
Sandler H: Defining biochemical failure following radiotherapy with or
without hormonal therapy in men with clinically localized prostate
cancer: recommendations of the RTOG-ASTRO Phoenix consensus
conference. Int J Radiat Oncol Biol Phys 2006, 65:965–974.
9. Rubin DB, Thomas N: Matching estimated propensity scores: relating
theory to practice. Biometrics 1996, 52:249–264.
10. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (Eds): AJCC
cancer staging manual. 7th edition. New York: Springer; 2010.
11. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL, ISUP Grading Committee:
The 2005 International Society of Urological Pathology (ISUP) consensus
conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol
2005, 29:1228–1242.
12. Grimm P, Billiet I, Bostwick D, Dicker AP, Frank S, Immerzeel J, Keyes M,
Kupelian P, Lee WR, Machtens S, Mayadev J, Moran BJ, Merrick G, Millar J,
Roach M, Stock R, Shinohara K, Scholz M, Weber E, Zietman A, Zelefsky M,
Wong J, Wentworth S, Vera R, Langley S: Comparative analysis of prostate-
specific antigen free survival outcomes for patients with low, intermediate
and high risk prostate cancer treatment by radical therapy: results from the
prostate cancer results study group. BJU Int 2012, 109:22–29.
13. Walz J, Joniau S, Chun F, Isbarn H, Jeldres C, Yossepowitch O, Chao-Yu H,
Klein EA, Scardino PT, Reuther A, Poppel HV, Graefen M, Huland H,
Karakiewics PI: Pathological results and rate of treatment failure in
high-risk prostate cancer patients after radical prostatectomy.
BJU Int 2010, 107:765–770.
14. Xylinas E, Daché A, Rouprȇt M: Is radical prostatectomy a viable
therapeutic option in clinically locally advanced [T3] prostate cancer?
BJU Int 2010, 106:1596–1600.
15. Soloway MS, Pareek K, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr,
Puras-Baez A, Lupron Depot Neoadjuvant Prostate Cancer Study Group:
Neoadjuvant androgen ablation before radical prostatectomy in
cT2bNxM0 prostate cancer: 5-year results. J Urol 2002, 167:112–116.
16. Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA,
Starkschall G, Rosen I: Preliminary results of a randomized radiotherapy
dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer.
J Clin Oncol 2000, 18:3904–3911.
17. Bolla M, Gonsalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J,
Kuten A, Sternberg C, Gil T, Collette L, Pierart M: Improved survival in
patients with locally advanced prostate cancer treated with
radiotherapy and goserelin. N Eng J Med 1997, 337:295–300.
18. Lee WR, Hanlon AL, Hanks GE: Prostate specific antigen nadir following
external beam radiation therapy for clinically localized prostate cancer:
the relationship between nadir level and disease free survival. J Urol
1996, 156:450–453.
doi:10.1186/1477-7819-12-134
Cite this article as: Koie et al.: Both radical prostatectomy following
treatment with neoadjuvant LHRH agonist and estramustine and
radiotherapy following treatment with neoadjuvant hormonal therapy
achieved favorable oncological outcome in high-risk prostate cancer:
a propensity-score matching analysis. World Journal of Surgical Oncology
2014 12:134.
